

UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases

NCT07441525

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Enrollment	27 participants

Key Eligibility Criteria

Inclusion (22)

- Subjects voluntarily participate in this trial and sign the informed consent form.
 - Aged e 18 years and d 75 years, regardless of gender.
 - Organ function and laboratory tests:
 - Liver function: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) d 3 x Upper Limit of Normal (ULN); Total Bilirubin (TBIL) d 2 x ULN (except for Gilbert's Syndrome).
 - Renal function: Creatinine d 1.5 x ULN or Creatinine Clearance Rate e 40 ml/min.
- ... and 17 more (see full listing online)

Exclusion (22)

- Has a coexisting autoimmune disease that may seriously interfere with the attribution of study disease activity or pose additional safety risks. However, if the subject's condition has been clinically stable for e 3 months, and it is expected not to interfere with study assessments, the subject may be enrolled after confirmation by the investigator and approval by the sponsor's medical monitor (or their designee).
 - Has rapidly progressive glomerulonephritis (RPGN), defined as any of the following:
 - Renal biopsy shows crescent formation in e 50% of glomeruli.
 - Sustained doubling of serum creatinine level within 2 months before screening.
 - The investigator assesses that the subject has RPGN.
- ... and 17 more (see full listing online)

Locations (1 total)

Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China